Last $5,219 MXN
Change Today +80.76 / 1.57%
Volume 47.0
BIIB* On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 4:08 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

225 Binney Street

Cambridge, MA 02142

United States

Phone: 781-464-2000

Fax:

Biogen Idec Inc., a biotechnology company, focuses on discovering, developing, manufacturing, and marketing therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases, and hemophilia. Marketed Products MS Products The company develops, manufactures and markets various products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, leading to a loss of muscle control, paralysis and, in some cases, death. AVONEX AVONEX is one of the most prescribed treatments for relapsing forms of MS worldwide. AVONEX is a recombinant form of the interferon beta protein produced in the body in response to viral infection. In 2012, the FDA approved two separate dosing innovations designed to improve the treatment experience for patients receiving once-a-week AVONEX for relapsing forms of MS: AVONEX PEN and a new dose titration regimen. AVONEX PEN is the first intramuscular autoinjector approved for MS and is designed to enhance the self-injection process for patients receiving AVONEX therapy. The dose titration regimen, facilitated by the AVOSTARTGRIP titration devices, provides patients with the option to gradually increase the dose of AVONEX at treatment initiation to reduce the incidence and severity of flu-like symptoms that patients may experience with therapy. These AVONEX dosing innovations are commercially available in the E.U., U.S. and other countries, and were approved for marketing in Japan. TYSABRI TYSABRI has advanced the treatment of relapsing MS with its established efficacy. TYSABRI is a monoclonal antibody approved in various countries as a monotherapy for relapsing MS and is also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. TECFIDERA TECFIDERA is its first-line oral treatment for people with relapsing forms of MS. TECFIDERA was approved by the FDA in 2013 and by regulatory authorities in Canada and Australia in April 2013 and July 2013, respectively. In February 2014, the EC approved the use of TECFIDERA in the E.U. as a first-line oral treatment for people with relapsing-remitting MS. TECFIDERA is also under review by regulatory authorities in additional markets. FAMPYRA FAMPYRA is the treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. FAMPYRA has been approved in approximately 50 countries across Europe, Asia and the Americas. The company has a license from Acorda Therapeutics, Inc. to develop and commercialize FAMPYRA in all markets outside the U.S. Other Products FUMADERM FUMADERM is approved for the treatment of moderate to severe plaque psoriasis in Germany. Psoriasis is a skin disease in which cells build up on the skin surface and form scales and red patches. RITUXAN RITUXAN is a prescribed monoclonal antibody used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. Non-Hodgkin's lymphoma and chronic lymphocytic leukemia are cancers that affect lymphocytes, which are a type of white blood cell that help to fight infection. Rheumatoid arthritis is a chronic disease that occurs when the immune system mistakenly attacks the body's joints, resulting in inflammation, pain and joint damage. ANCA-associated vasculitis is a rare autoimmune disease that largely affects the small blood vessels of the kidneys, lungs, sinuses, and a variety of other organs. In the U.S., the company collaborates with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, on the development and commercialization of RITUXAN. GAZYVA GAZYVA (obinutuzumab), injection for intravenous infusion, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia. Agreements In January 2014, the company entered into an exclusive worldwide collaboration and license agreement with Sangamo BioSci

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIIB*:MM $5,218.65 MXN +80.76

BIIB* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,703 JPY +47.50
Bristol-Myers Squibb Co $61.30 USD +0.51
Celgene Corp $117.18 USD +0.70
Novo Nordisk A/S kr266.00 DKK -0.50
Shire PLC 4,629 GBp -53.00
View Industry Companies
 

Industry Analysis

BIIB*

Industry Average

Valuation BIIB* Industry Range
Price/Earnings 33.5x
Price/Sales 9.3x
Price/Book 8.0x
Price/Cash Flow 28.3x
TEV/Sales 9.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN IDEC INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.